17β-estradiol reduced depressive and somatic symptoms in perimenopausal women


QUESTION: In perimenopausal women with clinically important depressive disorders, does 17β-estradiol decrease depressive symptoms?

Design
12 week randomised (allocation concealed*), blinded (clinicians, patients, outcome assessors, and statisticians†,* placebo controlled trial.

Setting
A gynaecological clinic and psychiatric outpatient clinic in São Paulo, Brazil.

Patients
50 women who were 40 to 55 years of age (mean age 50 y); had a history of menstrual cycle irregularity or amenorrhoea for < 12 months; had a serum concentration of follicle-stimulating hormone > 25 IU/l; and had been diagnosed with major depressive disorder, dysthymic disorder, or minor depressive disorder. Exclusion criteria were medical illness; hormone replacement therapy or psychoactive drug use in the previous 3 months; or presence of psychotic features or suicidal or severe aggressive behaviour. Follow up was 90%.

Intervention
Patients were allocated to a 17β-estradiol patch, 100 μg (Systen/Evorel, Janssen-Cilag Laboratories, São Paulo, Brazil) (n=25), or a placebo patch (n=25).

Main outcome measures
Severity of depressive symptoms measured by the Montgomery-Asberg Depression Rating Scale (MADRS) and severity of perimenopausal symptoms measured by the Blatt-Kupperman Menopausal Index (BKMI). Remission of depression was achieved if the MADRS score was < 10. A decrease of ≥ 50% from the baseline BKMI score was considered a significant improvement in somatic symptoms.

Main results
Analysis was by intention to treat. At 12 weeks, MADRS scores decreased more from baseline in women who received 17β-estradiol than in those who received placebo (−16.36 ± 4.16, 95% CI for the 12.9 difference in change from baseline 8.4 to 16.0, p < 0.001). More women who received estradiol had remission of depression (p=0.001) and a ≥ 50% decrease in BKMI scores (p=0.005) than did women who received placebo (table). The groups did not differ for adverse events. At the end of a 4 week washout period, MADRS scores remained lower than those at baseline in the estradiol group (p < 0.001) and were as severe as those at baseline in the placebo group (p=0.07).

Conclusion
In perimenopausal women with clinically important depressive disorders, 17β-estradiol decreased depressive and somatic symptoms.

*See glossary.
†Information provided by author.
‡CI calculated from data in article.
§Source of funding: Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)—São Paulo Research Foundation.

COMMENTARY
In the landmark study from Brazil by Soares et al of the 50 perimenopausal women enrolled, 52% met the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV), criteria for major depressive disorder, 26% for minor depressive disorder, and 22% for dysthymic disorder. The study had a 12 week treatment phase and a 4 week washout phase. A relatively high dose of oestrogen (100 μg) alone was used. Progesterone (which is the standard of care in women with a uterus or endometrium) was not used. 68% of women treated with transdermal 17β-estradiol had remission of depression, regardless of DSM-IV diagnosis, compared with 20% of women in the placebo group. The Massachusetts Women’s Health Study, a prospective 5 year observational trial, found no link between the onset of natural menopause and an increased risk for depression.1 However, women with a lengthy perimenopause apparently had moderately increased rates of depressive symptoms. Therefore, it is not surprising that mood disturbances, which may be higher in symptomatic perimenopausal women, would respond to oestrogen.

We need to determine which women with depressive symptoms benefit from oestrogen alone, oestrogen with a conventional antidepressant, or antidepressant treatment alone. Transdermal estradiol may be the best initial first-line treatment in women who have perimenopausal symptoms and minor mild-to-moderate mood symptoms, particularly if they do not have a uterus and do not need a progestin. Standard antidepressant treatment remains the first line of treatment for perimenopausal women with major depressive disorders alone.

We are moving beyond viewing oestrogen as only a reproductive hormone to viewing it as a neural hormonal agent with effects on mood and cognition.

Holly L. Thacker, MD
Cleveland Clinic Foundation
Cleveland, Ohio, USA